Biotech Event Tracker

274 events

Date	Symbol	Description	Type	Disease	Designation	Success Rating
05/09/2016	SPPI	Spectrum Pharmaceuticals (SPPI) PDUFA of Evomela for conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma	PDUFA	Oncology	Orphan Drug
05/11/2016	AAAP	Advanced Accelerator Applications (AAAP) Phase 3 Results of Lutathera for Neuroendocrine Tumors	Phase 3 Results	Oncology	Orphan Drug, Priority Review
06/01/2016	AAAP	Advanced Accelerator Applications (AAAP) PDUFA of Somakit-TATE for Neuroendocrine Tumors	PDUFA	Oncology	None, Orphan Drug, Priority Review
10/22/2016	OPK	OPKO (OPK) PDUFA of Rayaldee for Secondary Hyperparathyroidism	PDUFA	Endocrine	None
Q3 2016	ACRS	Aclaris Therapeutics (ACRS) Phase 2 Results of A-101 Topical Solution for Common Warts	Phase 2 Results	Other	None
Q3 2016	AERI	Aerie Pharmaceuticals (AERI) Top-Line Phase 3 Results of Roclatan for Glaucoma	Phase 3 Results	Opthamology	None
H2 2016	GWPH	GW Pharmaceuticals (GWPH) Phase 3 Results of Epidiolex for Dravet Syndrome and Lennox-Gastaut Syndrome	Phase 3 Results	Neurology	Fast Track, Orphan Drug
07/19/2016	VRX	Valeant (VRX) PDUFA of RELISTOR for Opioid-Induced Constipation	PDUFA	Other	None
07/01/2016	INSY	Insys Therapeutics (INSY) PDUFA of Syndros for Anorexia in Patients with AIDS and Nausea/Vomiting Associated with Chemotherapy	PDUFA	Oncology	None
Q2 2016	PRTK	Paratek Pharmaceuticals (PRTK) Phase 3 Results of Omadacycline for Acute Bacterial Skin Infections	Phase 3 Results	Infectious Disease	Fast Track